Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection.

Front Immunol · 2026 · PMC12894325 · PMID 41694404

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although Camre-Rivo (HR = 0.46; 95% CI, 0.21-1.03) yielded the most favorable point estimate, and Atezo-Bev (HR = 0.68; 95% CI, 0.42-1.10), Lenva (HR = 0.78; 95% CI, 0.56-1.09), and Sunit (HR = 0.89; 95% CI, 0.65-1.22) were numerically favorable, these differences did not reach statistical significance ( Figure 8 ). 3.2.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.